Given that an ideal biomarker should be differentially expressed in both the primary tissue affected by the disease but also be differentially expressed in peripheral blood, with its expression linked to disease phenotype or pathophysiological processes [85], FTH1 emerges as a promising biomarker for HD. This evidence concerns the gene FTH1 and Huntington disease.